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A B S T R A C T
Background
Most, if not all, of the cellular functions of the BRCA1 protein are mediated through
heterodimeric complexes composed of BRCA1 and a related protein, BARD1. Some breast-
cancer-associated BRCA1 missense mutations disrupt the function of the BRCA1/BARD1
complex. It is therefore pertinent to determine whether variants of BARD1 confer susceptibility
to breast cancer. Recently, a missense BARD1 variant, Cys557Ser, was reported to be at
increased frequencies in breast cancer families. We investigated the role of the BARD1
Cys557Ser variant in a population-based cohort of 1,090 Icelandic patients with invasive breast
cancer and 703 controls. We then used a computerized genealogy of the Icelandic population
to study the relationships between the Cys557Ser variant and familial clustering of breast
cancer.
Methods and Findings
The Cys557Ser allele was present at a frequency of 0.028 in patients with invasive breast
cancer and 0.016 in controls (odds ratio [OR]¼ 1.82, 95% confidence interval [CI] 1.11–3.01, p¼
0.014). The alleleic frequency was 0.037 in a high-predisposition group of cases defined by
having a family history of breast cancer, early onset of breast cancer, or multiple primary breast
cancers (OR ¼ 2.41, 95% CI 1.22–4.75, p ¼ 0.015). Carriers of the common Icelandic BRCA2
999del5 mutation were found to have their risk of breast cancer further increased if they also
carried the BARD1 variant: the frequency of the BARD1 variant allele was 0.047 (OR¼ 3.11, 95%
CI 1.16–8.40, p ¼ 0.046) in 999del5 carriers with breast cancer. This suggests that the lifetime
probability of a BARD1 Cys557Ser/BRCA2 999del5 double carrier developing breast cancer
could approach certainty. Cys557Ser carriers, with or without the BRCA2 mutation, had an
increased risk of subsequent primary breast tumors after the first breast cancer diagnosis
compared to non-carriers. Lobular and medullary breast carcinomas were overrepresented
amongst Cys557Ser carriers. We found that an excess of ancestors of contemporary carriers
lived in a single county in the southeast of Iceland and that all carriers shared a SNP haplotype,
which is suggestive of a founder event. Cys557Ser was found on the same SNP haplotype
background in the HapMap Project CEPH sample of Utah residents.
Conclusions
Our findings suggest that BARD1 Cys557Ser is an ancient variant that confers risk of single
and multiple primary breast cancers, and this risk extends to carriers of the BRCA2 999del5
mutation.
The Editors’ Summary of this article follows the references.
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Introduction
Since the discovery of the BRCA1 and BRCA2 genes, much
attention has been focused on characterizing the remaining
genetic risk of breast cancer. It is typically estimated that
strongly predisposing mutations in BRCA1 and BRCA2
account for 15%–25% of the familial component of the risk
[1,2]. Data from twin studies and studies of the high incidence
of cancer in the contralateral breast of patients surviving
primary breast cancer suggest that a substantial portion of
the uncharacterized risk of breast cancer is genetic, even in
the absence of a strong family history of the disease [3,4].
Model-fitting studies have indicated that the residual genetic
risk is likely to be polygenic in nature [5–7]. This predicted
genetic heterogeneity, together with the rather limited
success of family-based linkage studies, has led to a shift in
focus towards a search for genes with variants that are less
penetrant.
We and others have shown that there is a significant
familial risk of breast cancer in Iceland that extends to at
least fifth-degree relatives [8,9]. The contribution of BRCA1
mutations to familial risk in Iceland is thought to be minimal
[10,11]. A single founder mutation in the BRCA2 gene
(999del5) is present at a carrier frequency of 0.6%–0.8% in
the general Icelandic population and 7.7%–8.6% in female
breast cancer patients [12,13]. This single mutation is
estimated to account for approximately 40% of the inherited
breast cancer risk for first- through third-degree relatives [9].
Although this estimate is higher than the 15%–25% of
familial risk attributed to all BRCA1 and BRCA2 mutations
combined in non-founder populations, there is still some
60% of Icelandic familial breast cancer risk to be explained.
First-degree relatives of breast cancer patients who test
negative for BRCA2 999del5 remain at a 1.72-fold higher risk
for breast cancer than the overall population (95% CI 1.49–
1.96) [9]. The understanding of the genetic factors contribu-
ting to this residual risk is very limited.
The majority of the BRCA1 protein in vivo exists as
heterodimeric complexes with BARD1, an interaction medi-
ated through related RING finger domains present in both
proteins. The complex is important for the roles of BRCA1 in
homologous-recombination-directed DNA repair and tran-
scription-coupled repair [14,15]. The integrity of the BRCA1/
BARD1 complex is crucial for normal development, as both
BRCA1 and BARD1 knockout mice and frogs die as embryos
[16,17]. In most tissues, expression of BRCA1 and BARD1 is
regulated in a coordinated fashion [18]. Under- or over-
expression of either component can lead to apoptosis,
suggesting that an unbalanced expression or a disruption of
the complex activates pro-apoptotic effector functions [19–21].
The importance of the integrity of BRCA1/BARD1 com-
plexes is further underlined by the finding in breast cancer
families of missense mutations in the BRCA1 RING finger
domain. The common pathogenic substitutions C61G and
C64G occur in the zinc-binding residues of the BRCA1 RING
finger domain, disrupting its structure and abolishing its E3
ubiquitin ligase activity [22,23]. A relevant question is
whether mutations or variants in the BARD1 gene also
associate with breast cancer risk. Occasional reports have
appeared describing BARD1 variants in isolated cancer
families or as low-frequency population variants [24–27].
Recently, attention has focused on the Cys557Ser variant.
Cys557 occurs between the ankyrin repeats and BRCT
domains present on the BARD1 protein. This region has
been implicated in pro-apoptotic effector functions and
inhibition of the mRNA 39 end processing factor CstF1 [28–
30]. Ectopically expressed Cys557Ser protein shows defects in
growth-suppressive and pro-apoptotic functions, suggesting
that the variant may be pathogenic [31].
The Cys557Ser variant was first reported with a carrier
frequency of about 4% in a normal population with Euro-
pean ancestry [27]. Subsequently it was observed in an Italian
family with cases of breast and ovarian cancer, but was absent
from a control sample of 60 individuals without breast or
ovarian cancer [24]; recently, the Cys557Ser variant was found
at a frequency of 5.6% in Finnish families with a history of
breast and ovarian cancer and at a frequency of 7.4% in
families where breast cancer without ovarian cancer was
prevalent [26]. In this study, we sought to illuminate the role
of the BARD1 Cys557Ser variant in breast cancer using a
population-based case–control set representing all consent-
ing patients who were diagnosed with breast cancer in
Iceland between 1955 and 2004.
Materials
Patient and Control Selection
Approval for the study was granted by the National
Bioethics Committee of Iceland and the Icelandic Data
Protection Authority. Records of breast cancer diagnoses
were obtained from the Icelandic Cancer Registry (ICR) of
the Icelandic Cancer Society. The records included all cases
of invasive breast tumors and ductal or lobular carcinoma in
situ diagnosed in Iceland from 1 January 1955 to 31 March
2004. Ductal and lobular carcinoma in situ have been
recorded since 1955; however, in practice very few cases
were diagnosed prior to the initiation of the national breast
screening program in November 1987. There were 4,585
diagnoses in 4,306 individuals during this period. Of these,
4,255 diagnoses were invasive cancer and 330 were ductal or
lobular carcinoma in situ. For analyses of cancer risk and age
of onset, only International Classification of Diseases code 10
cases for invasive breast cancer in females were used. In
familial clustering analyses, in situ carcinomas and male
breast cancers were included. In situ carcinomas were also
considered as second primary tumors. ICR records were
histologically verified in over 95% of the cases. For analysis of
morphological subtypes, only histologically verified material
was used. Second primary tumors were confirmed both
clinically and by histology to be independent primary tumors,
arising simultaneously or subsequently to the first breast
cancer and occurring in the contralateral or ipsilateral breast.
In analysis of second primary tumors, all diagnoses of new
independent primaries were considered, so an individual
could have more than two tumors diagnosed. All living
patients with a diagnosis in the ICR were eligible for
participation in the study. Recruitment took place between
September 2003 and April 2005. During the recruitment
period, a total of 1,997 patients were alive and eligible to
participate. We were able to contact 1,926 (96%) of these
patients, and 1,431 (74% of those contacted) consented to
participate. Of the consenting patients, 1,241 (87%) were
successfully genotyped for the BARD1 variant. Patients were
asked to identify close relatives who could be invited to
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participate in the study. In this study, genotypic data from
relatives were used only to provide phase information for
BARD1 Cys557Ser-variant-associated single nucleotide poly-
morphism (SNP) haplotypes and for inheritance error
checking of the patients’ genotypes.
In order to generate the control group, we selected
randomly from the Icelandic genealogical database 1,034
triads (two parents and one offspring) with all individuals
between the ages of 18 and 70 y. The selected individuals were
invited to participate in the study, and 1,023 were recruited.
The medical histories of the controls were not investigated.
Genotyping was carried out for BARD1 Cys557Ser and
BRCA2 999del5. From among the successfully genotyped
individuals, only those who were unrelated to each other at a
distance of at least three meiotic events were selected for use
as controls. Where complete triads were available, the
parental component was used. This resulted in a group of
703 genotyped, unrelated individuals with a median age of 53
y and a sex ratio of 1.0. There was no difference in the carrier
frequencies of the BARD1 Cys557Ser variant between males
and females in the control group (p ¼ 0.40). Genotyped
offspring from triads, where available, were used to establish
phase information for the BARD1 Cys557Ser-variant-associ-
ated SNP haplotypes and for error checking of the controls’
genotypes. However, the offspring were not counted as
controls.
HapMap Project samples consisted of 30 triads from the
Centre d’Etude du Polymorphisme Humain (CEPH) popula-
tion (Utah, United States, residents with ancestry from
northern and western Europe); 45 unrelated Han Chinese
individuals from Bejing, China; 45 unrelated Japanese
individuals from Tokyo, Japan; and 30 triads from the Yoruba
population in Ibadan, Nigeria. Samples were obtained as
lymphoblastoid cell lines from the Coriell Institute for
Medical Research (Camden, New Jersey, United States).
Genotyping
All personal identifiers on samples, pedigrees, and medical
information were encrypted by representatives of the Ice-
landic Data Protection Authority prior to entry into the study
[32]. Blood samples were preserved in EDTA at20 8C. DNA
was isolated from whole blood or lymphoblastoid cell lines
using a Qiagen (http://www.qiagen.com) extraction column
method. Cys557Ser typing was carried out by DNA sequenc-
ing of BARD1 exon 7. Exon 6 was also sequenced in order to
read the genotypes of a number of public domain SNPs in
this exon. PCR amplifications and sequencing reactions were
set up on Zymark (http://www.zymark.com) SciClone ALH300
robotic workstations and amplified on MJR (http://www.mjr.
com) Tetrads. PCR products were verified for correct length
by agarose gel electrophoresis and purified using AMPure
(Agencourt Bioscience; http://www.agencourt.com). Purified
products were sequenced using an ABI PRISM Fluorescent
Dye Terminator system (PerkinElmer; http://www.perkinel-
mer.com), repurified using CleanSEQ (Agencourt), and
resolved on Applied Biosystems 3730 capillary sequencers.
SNP calling from primary sequence data was carried out
using deCODE Genetics (http://www.decode.com) Clinical
Genome Miner software. BRCA2 999del5 mutations were
detected using a microsatellite-type PCR assay. All BARD1
Cys557Ser and BRCA2 999del5 variants identified by the
automated systems were confirmed by manual inspection of
primary signal traces. Phase information for SNP haplotypes
was revealed by genotyping patients’ family members and by
genotyping triads from control and HapMap Project samples.
Phase and haplotype frequencies were determined using
deCODE Genetics Allegro and NEMO software [33,34].
Genealogical Database
deCODE Genetics maintains a computerized database of
the genealogy of Icelanders. The records include almost all
individuals born in Iceland in the last two centuries, and for
that period around 95% of the parental connections are
known [35]. In addition, a county-of-residence identifier is
recorded for most individuals, based on census and parish
records. The information is stored in a relational database
with encrypted personal identifiers that match those used on
the biological samples and ICR records, allowing cross-
referencing of the genotypes and phenotypes of the study
participants with their genealogies.
Statistical Methods
We calculate the odds ratio (OR) of the frequency of
BARD1 Cys557Ser as
OR ¼ ½ p=ð1 pÞ=½s=ð1 sÞ ð1Þ
where p and s are the frequencies of Cys557Ser in the patients
and the controls, respectively. Because the frequency of
Cys557Ser is low, ORs for allele frequencies are very similar
to ORs for carrier status in patients and controls. With
population controls, it can be shown through Bayes’s Rule
that the OR as defined above, and calculated for all breast
cancer patients, corresponds to Risk(carrier)/Risk(non-car-
rier) where Risk is the probability of breast cancer given
carrier status. p-Values associated with ORs were calculated
based on a standard likelihood ratio Chi-square statistic.
Confidence intervals were calculated assuming that the
estimate of OR has a log-normal distribution.
When OR is calculated using breast cancer patients who are
also carriers of BRCA2 999del5 compared to population
controls, OR is an estimate of the risk ratio of BRCA2 999del5
carriers who are also carriers of BARD1 Cys557Ser compared
to BRCA2 999del5 carriers who are not carriers of BARD1
Cys557Ser. This is because, by applying Bayes’s Rule and
assuming that BARD1 and BRCA2 are in linkage equilibrium
in the general population, it can be shown that
½PðBARD1CajBC;BRCA2CaÞ=PðBARD1NonCajBC;BRCA2CaÞ
½PðBARD1CaÞ=PðBARD1NonCaÞ
¼ PðBCjBARD1Ca;BRCA2CaÞ
PðBCjBARD1NonCa;BRCA2CaÞ ð2Þ
where BC denotes breast cancer, and Ca and NonCa denote
variant carrier and non-carrier, respectively. In other words,
when the OR is greater than one, it indicates that the risk for
BRCA2 999del5 carriers is further increased if they also carry
BARD1 Cys557Ser.
The 10-y risk for multiple primary tumors was determined
for each genotype class as (the number of secondary
diagnostic events/number of person-years of follow-up) 3
10. The total number of person-years of follow-up available
for analysis was 554 for BARD1 Cys557Ser carriers, 12,136 for
non-carriers of Cys557Ser, 492 for BARD1 Cys557Ser carriers
who were proven BRCA2 999del5 non-carriers, 11,371 for
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non-carriers of both BARD1 Cys557Ser and BRCA2 999del5,
817 for BRCA2 999del5 carriers, and 13,675 for 999del5 non-
carriers. Because it was possible for individuals to be
diagnosed with more than one additional primary tumor
after the first diagnosis, we employed a randomization
simulation strategy to determine the significance of the
frequencies of subsequent primary diagnoses. Significance
was assessed by 10,000 simulations in which carrier status was
assigned randomly among the tested individuals, and the
frequency of subsequent primary diagnoses was determined
for each simulation. An empirical p-value was then assigned
to the observed frequency of subsequent primary diagnoses
in carriers by reference to the distribution derived from the
simulations. Histological subclasses were analyzed by multi-
variate analysis with age taken into account as a continuous
covariate. In order to assess the significance of geographical
distributions of ancestors of Cys557Ser carriers, 1,000 lists of
random age- and sex-matched controls were generated from
the genealogical database. The geographical ancestry for each
list was traced back five generations, providing a null
distribution against which the observed distribution of
geographical ancestry for Cys557Ser carriers could be
compared. This allowed the statistical significance of geo-
graphical clustering in ancestry to be evaluated for each
county using an empirical p-value. Bonferroni correction was
applied in order to correct for the number of counties
evaluated. Age of onset comparisons were assessed by
Wilcoxon tests run on JMP version 4 software (SAS Institute;
http://www.sas.com). All p-values are reported as two-sided.
Results
The Frequency of the BARD1 Cys557Ser Variant Is
Increased in Icelandic Breast Cancer Cases
Breast cancer cases diagnosed in Iceland from January 1955
to March 2004 were ascertained from ICR records. A total of
1,090 patients diagnosed with invasive breast cancer were
successfully typed for the BARD1 Cys557Ser variant by DNA
sequencing. Population-based controls were selected ran-
domly from the national genealogical database. We used the
genealogical database to identify a set of 992 genotyped
patients and 703 controls who were unrelated to each other
by a distance of three meiotic events, in order to control for
the potential effect of relatedness among the groups. The
patients showed a significantly greater frequency of the
Cys557Ser allele than the controls (OR ¼ 1.82, 95% CI 1.11–
3.01, p ¼ 0.014; Table 1), demonstrating that the BARD1
variant confers risk for breast cancer in Iceland. Fifty-two
patients were heterozygous and two patients were homozy-
gous for the Cys557Ser variant. The homozygosity was
confirmed by analysis of six SNPs flanking the variant (see
below). All controls who carried the variant were hetero-
zygotes. Thus, the carrier frequency of Cys557Ser was 5.44%
in cases and 3.13% in controls.
Because the ICR records go back to 1955, some of the
patients we recruited were long-term cancer survivors. If
patients who carried Cys557Ser have different probabilities
of long-term survival than non-carriers, then the frequency of
the variant amongst prevalent cases might be affected. To
investigate this, the analysis was repeated on a subset of
patients composed of 310 unrelated individuals who were
diagnosed after 1 January 2000, with times from diagnosis to
recruitment of less than 5 y. In this cohort of recently
diagnosed patients the frequency of the Cys557Ser allele was
0.031, again significantly greater than for controls (OR¼ 1.99,
95% CI 1.07–3.70, p¼0.033). We also compared this cohort of
310 recently diagnosed patients to a group of 389 unrelated
patients who had been diagnosed before 1 January 1995 and
had survived to recruitment. The frequency of the Cys557Ser
allele in this group of long-term survivors was 0.026, which is
not significantly different from that of the recently diagnosed
patients (p ¼ 0.579). Therefore, there is no compelling
evidence for an influence of Cys557Ser on patient survival.
In order to assess the role of the Cys557Ser allele in
patients showing high predisposition to breast cancer, we
identified a set of patients who had two or more affected
relatives within three meiotic events, or who were members
of a pair related within three meiotic events, both of whom
were diagnosed at age 50 y or younger, or who had a recorded
diagnosis of a second independent primary tumor. This set of
patients was designated ‘‘high-predisposition breast cancer.’’
For each high-predisposition cluster identified, only a single
representative was chosen for analysis at random from the
genotyped individuals, resulting in a set of 190 independent
Table 1. Association of the BARD1 Cys557Ser Allele with Breast Cancer in Iceland
Phenotype Frequency of Cys557Ser Allele OR (95% CI) p-Value
Cases (n)a Controls (n)a
Breast Cancer (BC) 0.028 (992) 0.016 (703) 1.82 (1.11–3.01) 0.014
High-predisposition BCb 0.037 (190) 0.016 (703) 2.41 (1.22–4.75) 0.015
BC, BRCA2 999del5 carriers 0.047 (53) 0.016 (703) 3.11 (1.16–8.40) 0.046
BC, BRCA2 999del5 non-carriers 0.025 (949) 0.016 (703) 1.63 (0.98–2.71) 0.053 (N.S.)
High-predisposition BCb, BRCA2 999del5 carriers 0.063 (32) 0.016 (703) 4.20 (1.40–12.55) 0.028
High-predisposition BCb, BRCA2 999del5 non-carriers 0.032 (156) 0.016 (703) 2.08 (0.97–4.43) 0.071 (N.S.)
Shown are the allelic frequencies of the at-risk allele Cys557Ser in invasive breast cancer (BC) cases and controls, with the corresponding numbers of participants (n), the ORs, 95% CIs, and
p-values.
aIn total, 1,090 invasive breast cancer cases were genotyped for the Cys557Ser variant. For both cases and controls, subgroups were selected so that all members of each group were
unrelated to each other within at least three meioses.
bAffected probands who had two or more affected relatives within three meioses, or who were members of a pair related within three meioses, both of whom were diagnosed at 50 y of
age or younger, or who had a diagnosis of a second primary tumor.
N.S., not significant.
DOI: 10.1371/journal.pmed.0030217.t001
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high-predisposition probands. As shown in Table 1, the
frequency of the Cys557Ser allele was greater in this high-
predisposition group than in controls (OR ¼ 2.41, 95% CI
1.22–4.75, p ¼ 0.015). The point estimate of the OR was
nominally (but not significantly) higher than that observed
for patients who were not selected for high predisposition, as
would be expected of a genetic factor contributing modestly
to familial predisposition.
Since the BRCA2 999del5 mutation has such a substantial
impact on familial breast cancer in Iceland, we considered its
relationship with the BARD1 Cys557Ser variant. One possible
scenario would be that the BARD1 Cys557Ser variant confers
negligible additional risk to BRCA2 999del5 carriers, as has been
suggested for the interaction between CHEK2 and BRCA
mutations [36,37]. If this were so, then the frequency of the
BARD1 variant among affected BRCA2 999del5 carriers would
approximate the control frequency. Conversely, if the frequency
of the BARD1 variant in affected BRCA2 999del5 carriers is
greater than in the population controls, it would imply that the
BARD1 variant confers risk on the BRCA2 carriers over and
above the risk conferred by the 999del5 mutation (see Materials
for a more detailed discussion of this concept).
To investigate a potential risk from Cys557Ser in BRCA2
999del5 carriers, a set of unrelated 999del5 carriers was
identified among the 1,090 patients typed for the Cys557Ser
variant. The frequency of the Cys557Ser variant in 999del5
mutation carriers, both those not selected for family history
and those selected for high predisposition, was significantly
greater than in population controls (OR¼ 3.11, 95% CI 1.16–
8.40, p ¼ 0.046 for non-selected 999del5 carriers; OR ¼ 4.20,
95% CI 1.40–12.55, p¼ 0.028 for 999del5 carriers selected for
high-predisposition; Table 1). Therefore, BRCA2 999del5
carriers (who are already at high risk of breast cancer) have
their risk multiplied by an estimated factor of 3.11 if they also
carry the BARD1 Cys557Ser variant. These observations
demonstrate that the increased risk of breast cancer
conferred by the Cys557Ser variant extends to BRCA2
999del5 mutation carriers.
BARD1 Cys557Ser and Familial Clustering of Breast Cancer
It is well known that breast cancer tends to occur in familial
clusters [8,38]. The 1.82-fold increased risk of breast cancer
conferred by the BARD1 Cys557Ser variant will, by definition,
make a contribution towards familial clustering of affected
carriers. The overall degree of familial clustering in affected
Cys557Ser carriers will also depend on how the variant acts in
combination with other predisposition genes and environ-
mental factors shared within families. It is important to
assess, therefore, what proportion of patients who carry the
Cys557Ser variant have a family history of breast cancer. The
availability of the Icelandic genealogical database, along with
complete records of breast cancer diagnoses in Iceland since
1955, makes it possible to observe directly the tendencies of
BARD1 Cys557Ser variant carriers to participate in familial
clusters of breast cancer. Starting with the group of
Cys557Ser patients, we queried the genealogy for what
fraction of them were in one or more relative pairs, within
a distance of three meioses, with other patients in the group
of 4,306 patients in the ICR. In other words, we queried what
proportion of the variant carrier patients had at least one
first- or second-degree relative diagnosed with breast cancer.
We then queried what proportion of Cys557Ser variant
carriers had two or more, three or more, and four or more
affected relatives within the same genetic distance (Figure 1).
In order to put the analysis into context, we similarly tested
the tendency of BRCA2 999del5 mutation carriers to
participate in familial breast cancer clusters. We also tested
the clustering driven by several reference groups of breast
cancer patients: the 1,091 patients who were proven non-
carriers of either Cys557Ser or 999del5, the 1,209 patients
who had been tested for both Cys557Ser and 999del5
(regardless of the carrier status thereby identified), and the
entire group of 4,306 patients in the ICR records. The
tendency of the 703 control group members to participate in
familial breast cancer clusters was also examined. When
compared to the controls, the reference groups of breast
cancer patients all had more affected relatives, as expected
(Figure 1). The patients carrying the Cys557Ser variant also
had more affected relatives than the controls. They did not,
however, exhibit a markedly greater tendency to participate
in familial breast cancer clusters than the breast cancer
reference groups (Figure 1). Only the BRCA2 mutation
carriers showed a distinctly stronger tendency to contribute
to familial clusters than the reference groups. Therefore,
unlike BRCA2 breast cancer patients, patients who carry the
BARD1 variant do not present with family histories in a
frequency that would distinguish them from the overall
population of breast cancer patients.
Age at Diagnosis of Breast Cancer in Patients Carrying the
BARD1 Cys557Ser Variant
The median age at diagnosis of BARD1 Cys557Ser carrier
breast cancer patients was 55.1 y. This is not significantly
different from BARD1 non-carriers (median 55.9 y). The
median age of breast cancer diagnosis of BRCA2 999del5
carriers was 48.1 y, significantly younger than non-carriers of
Figure 1. Proportions of BARD1 Cys557Ser Patients, BRCA2 999del5
Patients, and Reference Groups of Patients Showing Family Histories of
Breast Tumors
For each member of the group of Cys557Ser carrier patients (n¼ 55), the
genealogical database and ICR records of diagnoses were searched to
identify all relatives with breast tumors within a distance of three
meioses. The proportion of Cys557Ser carriers who had one or more
affected relatives, two or more affected relatives, and so on is indicated.
For comparison, the analysis was repeated for BRCA2 999del5 patients (n
¼ 84), non-carriers of both BARD1 and BRCA2 variants (n ¼ 1,091), all
patients who were tested for both variants (n¼ 1,209), and all patients in
the ICR records (n ¼ 4,306). Controls were 703 individuals chosen
randomly from the genealogical database.
DOI: 10.1371/journal.pmed.0030217.g001
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e2171107
BARD1 Cys557Ser and Breast Cancer
the BRCA2 mutation (p , 0.001). Patients carrying both
BARD1 Cys557Ser and BRCA2 999del5 had a median age of
onset of 44.1 y; however, this was not significantly different
from 999del5-only carriers (p¼ 0.498). The two patients who
were shown to be homozygous for the Cys557Ser variant had
quite early onset of the disease, at ages 41 and 47 y. Neither of
the Cys557Ser homozygotes were 999del5 carriers.
Increased Incidence of Multiple Primary Breast Tumors in
BARD1 Cys557Ser Carriers
The occurrence of multiple primary tumors is an indica-
tion of hereditary breast cancer predisposition. Therefore, we
determined whether multiple primary breast tumors (invasive
or in situ) occurred at higher than expected frequencies in
Cys557Ser carriers (Table 2). The mean follow-up time (from
diagnosis to recruitment) for the entire cohort was 10.3 y. We
determined the 10-y risk for multiple primary tumors and
compared risks of carriers and non-carriers to determine risk
ratios. Significance was assessed by empirical p-values derived
from 10,000 simulations of individuals with randomly
assigned carrier status. As shown in Table 2, the risk of
multiple primary tumors was more than doubled in BARD1
Cys557Ser carriers compared to non-carriers. Interestingly,
the risk of multiple primary tumors was also increased among
BARD1 Cys557Ser carriers who had tested negative for
BRCA2 999del5 mutations, indicating that the effect of the
BARD1 variant is not restricted to BRCA2 mutation carriers.
The risk of second primary breast tumors was significantly
greater in the group of all BRCA2 999del5 mutation carriers
than in non-carriers, as expected.
The BARD1 Cys557Ser Variant Is Overrepresented in
Lobular and Medullary Carcinomas of the Breast
We next sought to determine whether the Cys557Ser
variant associates preferentially with specific histological
classes of breast cancer as defined by SNOMED morphology
codes (http://www.snomed.org). The most frequent histolog-
ical class in both carriers and non-carriers was infiltrating
ductal carcinoma, as expected (Table 3). However, there was a
significant difference in the distribution of the less common
histological classes, with an approximate 2.5-fold excess of
lobular carcinoma and 6.9-fold excess of medullary carcino-
ma among carriers of the Cys557Ser variant. Carcinomas in
situ were absent from Cys557Ser carriers, whereas they were
present at a frequency 12% in non-carriers (age-adjusted p,
0.001), suggesting more aggressiveness of BARD1 variant
tumors. The analysis of histological classes was repeated
excluding carcinoma in situ diagnoses, and showed a
significant difference in distribution of the invasive histo-
logical types between carriers and non-carriers (age-adjusted
p ¼ 0.011).
The Geographical Ancestry of the BARD1 Cys557Ser
Variant Can Be Traced to a Single County in the South East
of Iceland
Icelanders are now highly urbanized, but in the past
regional subpopulations were more isolated [39]. By examin-
ing the geographical distribution of ancestors for a group of
individuals carrying a given genetic variant, it is possible to
shed light on the history of the variant. In particular, this
approach can indicate the nature and extent of a possible
Table 2. The Risk of Multiple Primary Tumors in BARD1 Cys557Ser and BRCA2 999del5 Carriers
Phenotype Number of First
Primary Diagnosesa
Number of Additional
Primary Diagnoses
Mean Follow-Up
Time (Years)
Risk at
10 y
OR p-Valueb
Cys557Ser carriers 55 9 10.1 0.162 2.32 0.044
Cys557Ser non-carriers 1,178 85 10.3 0.070
Cys557Ser carriers, 999del5 non-carriers 49 8 10.0 0.163 2.72 0.019
Cys557Ser and 999del5 non-carriers 1,098 68 10.4 0.060
999del5 carriers 83 19 9.8 0.233 3.66 ,0.001
999del5 non-carriers 1,325 87 10.3 0.064
aOnly individuals who were tested successfully for the variant(s) under scrutiny were included in analyses.
bEmpirical p-values were determined by simulations of 10,000 randomized permutations of variant carrier status.
DOI: 10.1371/journal.pmed.0030217.t002
Table 3. Distribution of Histological Subtypes of First Primary Breast Tumor Diagnoses in BARD1 Cys557Ser Carriers and Non-Carriers
Histological Subtypes (SNOMED) Cys557Ser Carriers Cys557Ser Non-Carriers
Number of Cases Frequency Number of Cases Frequency
Infiltrating ductal carcinoma 39 0.709 753 0.640
Lobular carcinoma 8 0.145 68 0.058
Medullary carcinoma 3 0.055 10 0.008
Carcinoma in situ 0 0 142 0.120
Other 5 0.091 204 0.173
Total 55 1,177
Age adjusted logistic regression, p , 0.001.
DOI: 10.1371/journal.pmed.0030217.t003
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founder effect in the history of the BARD1 Cys557Ser variant
and whether the ancestors from whom modern Icelanders
have inherited the variant lived predominantly in a particular
region of Iceland.
For each Cys557Ser carrier identified in the study
(irrespective of breast cancer affection status) all the known
ancestors five generations back were identified, yielding a
maximum number of 32 (25) ancestors for each contemporary
carrier. The proportions of ancestors originating from each
county were then determined. In order to determine whether
particular counties were overrepresented or underrepre-
sented among the ancestors, the geographic ancestries of
1,000 lists of random age- and sex-matched controls were
traced, and empirical p-values were determined. As shown in
Figure 2, ancestors of BARD1 variant carriers originated
more often than expected from the county of S-Mu´lasy´sla, an
isolated region in the east of Iceland. An excess of ancestry,
although not reaching significance, was also detected in the
adjacent county A-Skaftafellssy´sla. Ancestors of all the
individuals tested for the BARD1 variant (irrespective of the
variant carrier status identified) did not show a geographical
localization to S-Mu´lasy´sla, indicating that the overall sample
collection was not biased towards individuals with ancestry
from that region (data not shown). The excess of geographical
ancestry of Cys557Ser carriers in S-Mu´lasy´sla indicates that
most copies of the variant now present in Iceland originated
from a relatively small number of ancestors who resided in a
single geographical region prior to the expansion of the
Icelandic population from approximately 40,000 at the end of
the 18th century to its current size of 300,000 [39]. The
Cys557Ser variant is therefore likely to have been consid-
erably more frequent in S-Mu´lasy´sla than in the rest of the
country five generations ago, pointing to the occurrence of a
geographically localized founder effect.
We examined whether the geographical distribution of the
contemporary carriers of Cys557Ser or that of their ancestors
may have confounded the association between the variant
and breast cancer. We performed multivariate analyses taking
into account the geographical origins of the patients and
controls themselves or their fifth-generation ancestors as
covariates. In both cases, the relative risks of breast cancer in
BARD1 variant carriers were unchanged and the significance
of the findings was maintained (p ¼ 0.032 and 0.023 when
adjusted for contemporary patients’ geographical origins and
the origins of the fifth-generation ancestors, respectively).
Therefore, we conclude that the geographical distribution of
the BARD1 variant, either now or in the past, does not
explain its association with the disease.
Icelandic BARD1 Cys557Ser Variants Have a Common
Origin
The data from the International HapMap Project (CEU;
HapMap Phase I, version 16c.1) indicated that the BARD1
gene is fully encompassed by a single linkage disequilibrium
block extending approximately between coordinates 215.8
Mb and 216.0 Mb on Chromosome 2. We used a number of
public domain SNPs in and near exon 6 of the BARD1 gene to
search for a haplotype background (or backgrounds) of the
Cys557Ser variant. The exon 6 SNPs were typed by DNA
sequencing in carriers and non-carriers of the variant,
including a sample of their relatives in order to establish
haplotype phase. A single SNP background was identified in
all carriers tested (haplotype frequency 0.55, n ¼ 53) and in
none of 1,197 non-carriers (Table 4). This indicates a
probable common origin for all the Icelandic BARD1
Cys557Ser variants.
To further investigate the origins of Cys557Ser, we typed
the variant in the four ethnic cohorts from the HapMap
Project. The Cys557Ser variant was absent from the Han
Chinese (n ¼ 45), Japanese (n ¼ 45), and Yoruba (30 triads).
Three unrelated individuals in the CEPH sample of Utah
residents with ancestry from northern and western Europe (n
Figure 2. Geographical Ancestry of All Known BARD1 Cys557Ser Carriers
Red bars indicate the locations of ancestors in the fifth generation back for Cys557Ser carriers, and yellow bars represent the average number of
ancestors expected for each county based on 1,000 lists of randomly selected age- and sex-matched controls. One county in the east, S-Mu´lasy´sla
(shaded in blue), shows an excess of BARD1 Cys557Ser ancestors that retained significance after Bonferroni correction. Two counties (shaded in pink)
exhibited a marginally significant deficit of BARD1 Cys557Ser ancestors, which did not survive Bonferroni correction.
DOI: 10.1371/journal.pmed.0030217.g002
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¼ 90) were identified as carriers. These individuals shared a
176-kb haplotype of SNPs selected to tag the BARD1 linkage
disequilibrium block (Table 4). The haplotype was absent
from non-carriers. In order to relate this haplotype to the
Icelandic SNP haplotype, the series of BARD1 exon 6 SNPs
was typed in the CEPH Utah samples. As shown in Table 4,
the haplotype defined by the HapMap tagging SNPs was
completely concordant with the Icelandic SNP haplotype. We
concluded that the BARD1 variants present in Iceland and in
the CEPH Utah samples have a common origin.
Discussion
In this study, we report that the BARD1 Cys557Ser variant
confers risk of breast cancer and that the risk extends to
carriers of the Icelandic BRCA2 999del5 mutation. Carriers
of the Cys557Ser variant who had breast cancer were also
found to be at increased risk for developing multiple
independent primary tumors.
Soon after the discovery of BARD1 as a BRCA1-interacting
protein, studies were initiated to investigate a possible
contribution of BARD1 variants to risk of breast cancer.
Several variants were found in rare breast cancer families or
in control populations; however, their contribution to the
risk of disease has been uncertain [24,25,27]. Recently, the
Cys557Ser variant was reported at increased frequency in
hereditary breast cancer probands from Finland [26]. Here
we confirm that the frequency of Cys557Ser is increased
among patients with a high predisposition to breast cancer.
We extend this observation to show that the frequency is
increased in patients who were not selected for high-
predisposition characteristics. We estimate an approximately
1.8-fold increase in risk conferred by the BARD1 variant,
corresponding to a population attributable risk of about
2.5%. Taken in isolation, this finding does not appear to
make a great contribution to potential genetic testing for
breast cancer risk. However, given the current view that the
residual hereditary risk of breast cancer may be characterized
by extensive genetic and allelic heterogeneity [6,7,40], it is
important to identify all components of the complex genetic
risk. This may be a painstaking task. It has been estimated
that for predisposition alleles with frequencies and risks in
the range of the Cys557Ser variant, some 250–400 different
genes or alleles would be required to account for the relative
risk of approximately 1.8 to first-degree relatives observed for
breast cancer [41,42].
Karppinen et al. [26] reported that the frequency of the
Cys557Ser variant is significantly elevated only in groups of
patients with familial breast cancer. These data are similar to
the initial reports for CHEK2, where the 1100delC variant
was found at significantly increased frequency only in familial
breast cancer patients [37,43]. In our study we demonstrate
significantly increased frequencies of the BARD1 variant in
breast cancer patients who were not selected for family
history and in probands representing high-predisposition
clusters of patients. Our point estimates of ORs were slightly
greater for the high-predisposition patients, although the
differences were not significant (OR¼1.82, 95% CI 1.11–3.01,
versus OR ¼ 2.41, 95% CI 1.22–4.75, for high-predisposition
breast cancer). It is important to consider what these
combined observations imply regarding the contribution of
the low-penetrance alleles to familial breast cancer. Two
factors contribute to the increased prevalence of a risk allele
in familial or high-predisposition patients. First, by defini-
tion, a genetic risk variant must be responsible for some
familial clustering of the disease. Second, further increased
familial clustering of affected carriers may result from the
variant acting in concert with other predisposition determi-
nants. Since such interactions are largely unknown or
difficult to measure, it is of interest to observe directly the
tendency of variant carriers to participate in familial breast
cancer clusters. We show that while BARD1 Cys557Ser
Table 4. Haplotype Background of the Cys557Ser Variant
Physical Location
(Basepairs)a
Marker
Nameb
Marker Type/
Comment
Distance
to Cys557
(Basepairs)
Icelandic
Genotype
CEPH Utah
Genotypec
215802799 rs895459 TagSNP 16,921 C
215819720 SG02S284 Cys557Ser 0 C C
215831203 rs4673896 TagSNP 11,483 C
215834590 rs6413460 Exon 6 SNP 14,870 A A
215834667 rs5031007 Exon 6 SNP 14,947 A A
215834697 rs5031009 Exon 6 SNP 14,977 G G
215834706 SG02S356 Exon 6 SNP 14,986 T T
215834734 rs5031011 Exon 6 SNP 15,014 C C
215834797 rs2070094 Exon 6 SNP 15,077 A A
215834798 rs2070093 Exon 6 SNP 15,078 C C
215858461 rs3768704 TagSNP 38,741 A
215960701 rs7560809 TagSNP 140,981 A
215968833 rs943293 TagSNP 149,113 G
215978545 rs6739178 TagSNP 158,825 G
The occurrence of the background haplotype (bold) in Cys557Ser carriers was 53/53 for the Iceland samples and 3/3 for the CEPH Utah samples, and for Cys557Ser non-carriers was 0/
1,197 for the Iceland samples and 0/87 for the CEPH Utah samples.
aNCBI Build 34 hg16 July 2003 assembly.
bMarkers with prefix SG generated by deCODE Genetics.
cDerived from the HapMap CEPH sample of Utah residents with ancestry from northern and western Europe.
DOI: 10.1371/journal.pmed.0030217.t004
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contributes to familial clustering of breast cancer, the effect
does not exceed the innate tendency of the general
population of breast cancer patients to form familial clusters.
This tendency most probably reflects the uncharacterized
genetic risk determinants segregating in the background
breast cancer population. The practical implication of this
observation is that most patients carrying the BARD1
Cys557Ser variant will present without a distinctive family
history of breast cancer.
This is not to say that the BARD1 variant is trivial in
familial breast cancer. We show that the risk conferred by the
BARD1 Cys557Ser variant extends to BRCA2 999del5
carriers. It has been known for some time that different
BRCA2-999del5-mutation-carrying families exhibit varying
penetrances for breast cancer [12]. The BARD1 Cys557Ser
variant is clearly a factor contributing to this variation. We
estimate that the risk of breast cancer in a 999del5 carrier
who also carries Cys557Ser is more than 3-fold greater than
the risk in a 999del5 carrier who does not carry the BARD1
variant. Even though the confidence intervals on this estimate
are wide (95% CI 1.16–8.40), given that BRCA2 999del5
carriers have a lifetime probability of developing breast
cancer in excess of 40%, the combined risk to a Cys557Ser/
999del5 double carrier could approach certainty. A positive
test for Cys557Ser in a BRCA2 carrier might, therefore, have
serious clinical implications.
We did not see a significant difference between the OR for
Cys557Ser in BRCA2 carriers versus BRCA2 non-carriers
(Table 1). Therefore, the factor by which an individual’s
baseline risk is multiplied because of the presence of
Cys557Ser may be the same regardless of their BRCA2 carrier
status. However, since the baseline risk for BRCA2 mutation
carriers is already high, the same multiplicative factor results
in a very much greater increase in absolute risk in BRCA2
carriers than in BRCA2 non-carriers.
Our estimate of risk from BARD1 Cys557Ser in BRCA2
999del5 carriers assumes that the two variants are in linkage
equilibrium in the population. Since the two genes are on
different chromosomes, this is a reasonable assumption. All
control individuals were genotyped for both the BARD1 and
BRCA2 variants. This genotyping revealed no evidence to
support a deviation from linkage equilibrium that might
account for the increased frequencies of BARD1 Cys557Ser in
BRCA2 999del5 carriers, although the power to detect a
disequilibrium is limited by the low frequencies of variant
carriers among the controls.
The observation of Cys557Ser risk extending to BRCA2
carriers contrasts markedly with reports of the interactions
between the CHEK2 1100delC variant and BRCA mutations
[36,37,43]. In the studies published to date, no CHEK2
mutation carriers have been found among BRCA mutation
carriers. This underrepresentation of CHEK2 1100delC, while
not statistically significant, is inconsistent with a multi-
plicative model of risk. It has been suggested that the paucity
of BRCA mutations amongst CHEK2 1100delC carriers
reflects the functional redundancy of pathways affected by
BRCA and CHEK2 [36,37]. It is questionable whether BARD1
and BRCA2 operate in the same biological pathways. The
majority of BARD19s biological activity is thought to be
mediated through the complex with BRCA1; the interactions
between BRCA1 and BRCA2 in homologous-recombination-
directed DNA repair are well characterized. However, BARD1
and BRCA1 function additionally in transcription-coupled
repair, where a role for BRCA2 has not been demonstrated
[18]. BARD1 and BRCA2 pathways therefore may not overlap
to the same extent as those of the CHEK2 and BRCA proteins
do. The best example of overlapping pathways would of
course be BARD1 and BRCA1, so it would be of great interest
to investigate the risk from BARD1 Cys557Ser variants
amongst BRCA1 mutation carriers. Such studies are not
sufficiently well powered in Iceland because of the low
frequency of carriers of known BRCA1 mutations [11].
The identification of individuals homozygous for BARD1
Cys557Ser demonstrates that the variant is not a recessive
lethal, in contrast to observations that BARD1 knockout is
lethal in mice and that knockdown mice show evidence of
haploinsufficiency [16,17]. This would suggest that the BARD1
Cys557Ser variant protein has residual function or that
redundant pathways exist in humans. The Cys557Ser variant
protein has been shown to be defective in growth suppression
and the induction of apoptosis [31]. Further functional
studies on the BARD1 protein in general and the Cys557Ser
variant in particular are clearly warranted.
Lobular carcinoma is associated with familial risk of breast
cancer [38,44–46]. Familial non-BRCA cancers have a higher
frequency of invasive lobular carcinoma than BRCA1 cancers,
suggesting that there is an uncharacterized genetic predis-
position involving this tumor type [47]. The BARD1
Cys557Ser variant may contribute to this predisposition.
There are also indications of an association between
medullary cancer and familiality [44,48]. Medullary and
atypical medullary carcinoma have been associated with
BRCA1 mutation carriers [49,50]; however, this finding has
not been universal [51–54]. Partly, inconsistencies may arise
because BRCA1 tumors exhibit certain morphological char-
acteristics that are found in medullary carcinoma, but are not
unique to this histological type [48]. Moreover, the associa-
tion may be confounded because the largest studies used big
multicancer families or groups with early-onset disease. It is
possible that high-penetrance BRCA1 families may co-
segregate other genetic factors that predispose to medul-
lary-carcinoma-associated morphologies. One may speculate
that the BARD1 Cys557Ser variant plays a role here, but
resolution of this point would again require the identification
of a sufficient number of BRCA1-mutant BARD1 Cys557Ser
variant carriers.
The Cys557Ser variant has now been reported in samples
from Iceland, Finland, and Italy, and in Americans of
European descent, suggesting that its presence in Iceland
was a result of migration rather than a de novo mutation
[24,26,27]. Indeed, our finding of the same SNP haplotype
among variant carriers in Iceland and in the CEPH Utah
sample suggests a single ancient mutation that has become
geographically widespread in European-descendant popula-
tions. In Iceland, the variant displays the characteristics of a
founder effect over the last one and a half centuries. The
geographical ancestry indicates that five generations ago the
frequency of the variant was considerably higher in one
isolated region than in the rest of the country and that most
present-day copies of the variant originate from that region.
The origin of this founder effect is likely to be attributable to
a combination of factors including genetic drift, limited gene
flow between counties, and a greater number of Cys557Ser
carriers amongst the first settlers of S-Mu´lasy´sla.
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We and others did not find the BARD1 Cys557Ser variant
in samples from Yoruba, Chinese, Japanese, and African-
American individuals [25,27]. Therefore, the variant may be
restricted to individuals with European ancestry and could
contribute to the higher load of breast cancer seen in this
group [55]. However, other BARD1 variants have been
discovered in African-American and Japanese individuals
[25,27]. The contribution of these variants to the risk of
disease is still uncertain.
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Editors’ Summary
Background. About 13% of women (one in eight women) will develop
breast cancer during their lifetime, but many factors affect the likelihood
of any individual woman developing this disease, for example, whether
she has had children and at what age, when she started and stopped her
periods, and her exposure to certain chemicals or radiation. She may also
have inherited a defective gene that affects her risk of developing breast
cancer. Some 5%–10% of all breast cancers are familial, or inherited. In
20% of these cases, the gene that is defective is BRCA1 or BRCA2.
Inheriting a defective copy of one of these genes greatly increases a
woman’s risk of developing breast cancer, while researchers think that
the other inherited genes that predispose to breast cancer—most of
which have not been identified yet—have a much weaker effect. These
are described as low-penetrance genes. Inheriting one such gene only
slightly increases breast cancer risk; a woman has to inherit several to
increase her lifetime risk of cancer significantly.
Why Was This Study Done? It is important to identify these additional
predisposing gene variants because they might provide insights into
why breast cancer develops, how to prevent it, and how to treat it. To
find low-penetrance genes, researchers do case–control association
studies. They find a large group of women with breast cancer (cases) and
a similar group of women without cancer (controls), and examine how
often a specific gene variant occurs in the two groups. If the variant is
found more often in the cases than in the controls, it might be a variant
that increases a woman’s risk of developing breast cancer.
What Did the Researchers Do and Find? The researchers involved in
this study recruited Icelandic women who had had breast cancer and
unaffected women, and looked for a specific variant—the Cys557Ser
allele—of a gene called BARD1. They chose BARD1 because the protein it
encodes interacts with the protein encoded by BRCA1. Because defects
in BRCA1 increase the risk of breast cancer, defects in an interacting
protein might have a similar effect. In addition, the Cys557Ser allele has
been implicated in breast cancer in other studies. The researchers found
that the Cys557Ser allele was nearly twice as common in women with
breast cancer as in control women. It was also more common (but not by
much) in women who had a family history of breast cancer or who had
developed breast cancer more than once. And having the Cys557Ser
allele seemed to increase the already high risk of breast cancer in women
who had a BRCA2 variant (known as BRCA2 999del5) that accounts for
40% of inherited breast cancer risk in Iceland.
What Do These Findings Mean? These results indicate that inheriting
the BARD1 Cys557Ser allele increases a woman’s breast cancer risk but
that she is unlikely to have a family history of the disease. Because
carrying the Cys557Ser allele only slightly increases a woman’s risk of
breast cancer, for most women there is no clinical reason to test for this
variant. Eventually, when all the low-penetrance genes that contribute to
breast cancer risk have been identified, it might be helpful to screen
women for the full set to determine whether they are at high risk of
developing breast cancer. This will not happen for many years, however,
since there might be tens or hundreds of these genes. For women who
carry BRCA2 999del5, the situation might be different. It might be worth
testing these women for the BARD1 Cys557Ser allele, the researchers
explain, because the lifetime probability of developing breast cancer in
women carrying both variants might approach 100%. This finding has
clinical implications in terms of counseling and monitoring, as does the
observation that Cys557Ser carriers have an increased risk of a second,
independent breast cancer compared to non-carriers. However, all these
findings need to be confirmed in other groups of patients before anyone
is routinely tested for the BARD1 Cys557Ser allele.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030217.
 MedlinePlus pages about breast cancer
 Information on breast cancer from the United States National Cancer
Institute
 Information on inherited breast cancer from the United States
National Human Genome Research Institute
 United States National Cancer Institute information on genetic testing
for BRCA1 and BRCA2 variants
 GeneTests pages on the involvement of BRCA1 and BRCA2 in
hereditary breast and ovarian cancer
 Cancer Research UK’s page on breast cancer statistics
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